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Lung disease claims nearly half a million lives in the U.S. alone, placing it as the 
third leading cause of death. Chronic pulmonary disorders, marked by excessive 
extracellular matrix deposition (ECM), such pulmonary fibrosis, are the most resistant to 
present clinical therapies resulting in prognoses of 50% life expectancy three years from 
diagnosis. Inadequacies of current treatments may be attributable to limitations in non-
invasive therapeutic administration modalities. However, with the use of polyketal 
microparticles (PKMs), a novel drug delivery vehicle, a myriad of therapeutic schemes 
may be explored. Polyketals are a new polymeric family characterized by excellent 
tissue biocompatibility, rapid hydrolysis, and benign degradation byproducts making it 
attuned for pulmonary applications. Potential treatments such as siRNA, oligo 
nucleotides, peptides, enzymes and other biomolecules can be encapsulated within 
PKMs and administered non-invasively via inhalation. 
For this study, we selected a model therapeutic peptide, Ac-SDKP, with 
established anti-fibrotic properties as the “load” for PKMs. For those lung dysfunctions 
characterized by pathological ECM remodeling accompanied by fibrotic scarring, Ac-
SDKP possesses promise in restoring the normal ECM framework. To assess PKMs 
viability as a pulmonary drug delivery vehicle three objectives were initially defined: 1) 
Synthesize particles possessing aerodynamic properties conducive for aerosolization 
with low polydispersity, 2) Optimization of the therapeutic load, Ac-SDKP, in PKMs to 
levels that will translate to reasonable clinical dosing concentrations, and 3) Determine 
the biocompatibility of the PKMs in the lung. 
Optimization of the Ac-SKDP loading within PKMs and size analysis revealed 
that a solid in oil in water double emulsion particle synthesis technique produced the 





when locally dispensed into the alveolar space, should reach clinical dosing 
requirements. Synthesized particles were compatible with aerosolization criteria; i.e., 
diameters below 3 µm and low polydispersities. The relatively low particle size 
distributions should promote uniform particle dissemination and hydrolysis allowing 
therapeutic release to be consistent. In addition, we evaluated PKM tissue 
biocompatibility using a murine lung model. Examination of bronchoalveolar lavage fluid 
demonstrated only a slight inflammatory response to intratracheal particle injections of 
PKMs whereas PLGA, a commonly used biomaterial, elicited a significantly higher 
response. Histological assessment of the lungs following particle injection verified PKMs’ 
biocompatibility superiority.  In conclusion, small-diameter PKMs (1-3 µm) are a suitable 
delivery system for pulmonary drug delivery, capable of delivering small peptide 
therapeutics and evading the local inflammatory response. The present work will enable 






















1.1 Background and Significance 
Displaying increasing incidence, lung disease is the third leading cause of death 
resulting in over 350,000 American fatalities annually. Significant contributions to 
pulmonary disease morbidity are those classified as chronic lung disease in which 35 
million U.S. citizens are afflicted (American Lung Association). This class of lung 
pathology includes common disorders such as chronic obstructive pulmonary disease 
(COPD) (i.e. chronic bronchitis and emphysema), bronchopulmonary dysplasia (BPD), 
and interstitial lung disease (ILD). Although, the onset of these disorders is diverse, all 
are characterized by incurable compromised lung function largely due to pathological 
tissue remodeling. The pathophysiology of these chronic lung diseases often result in 
fibrotic scarring and stiffening of pulmonary structures that disrupt essential respiratory 
processes. Resultant clinical symptoms can manifest as shortness of breath, wheezing, 
severe cough, and low blood oxygen levels (American Lung Association). With lung 
disease prevalence failing to diminish, it is evident the efficacy of standard clinical 
treatments is inadequate. 
Management techniques of certain chronic lung diseases have higher success than 
others, but none are considered a cure. For instance BPD, a disease characterized by 
lung inflammation and scarring in premature infants, can be partially resolved with 
current treatments (Ashour et al. 2006).  This can include high oxygen therapy, use of 
bronchodilators and low-pressure lung ventilation systems.  These treatments solely 
focus on supporting the oxygen needs of the infant while symptoms of the BPD subside 
as the child develops. However, they do little to combat the source of the lung 





COPD also include oxygen therapy, use of bronchodilators as well as inhalable 
corticosteroids to treat inflammation. Again, the pathophysiology of the disease causing 
airflow restriction and lung tissue remodeling is not effectively addressed (Barnes 2000).  
This can potentially lead to survival projections only of ten years if diagnosis and 
treatment is delayed. Perhaps, the most resistant of all to current treatments is interstitial 
lung disease or more specifically pulmonary fibrosis. This disease, marked by 
progressive lung scarring and stiffening, causes up to 50,000 American deaths each 
year. To date, there exists no therapeutic that impedes the advancement of the disease 
or averts its onset. As a result, pulmonary fibrosis has one of the gravest prognoses with 
50% life expectancy 3 years from diagnosis.  
In general, current treatments for chronic lung diseases focus on alleviating the 
symptoms and not the source of the ailment. This potentially is due to limiting 
therapeutic administration modalities. Currently, therapies are restricted to oral 
supplements, intravenous routes, or medications capable of achieving an inhalable form.  
Oral and intravenous modes of treatment leave patients susceptible to undesirable 
systemic side effects especial with routinely used immunosuppressing corticosteroids 
(Mapel, D.W. et al. 1996). With a novel delivery system, varieties of locally dispensed 
therapeutic schemes can be expanded, substantially minimizing risk of systemic side 
effects. Utilizing polyketal microparticles as a drug delivery vehicle, vast strides can be 
made with treatments of lung diseases, especially pulmonary fibrosis. Polyketal 
microparticles (PKMs) are composed of a biocompatible, biodegradable polymer 
capable of encapsulating small molecule therapeutics, allowing for a controlled release 
of drug while minimizing the induction of inflammation (Dailey, L.A., et al 2006). 
Appropriately sized, in the range 1-3 um for non-porous particles, PKMs have the 





inhalation (Cryan, S.A. 2005).   Use of PKMs could permit delivery of siRNA, enzymes, 
oligo nucleotides, small peptides or other promising therapeutics that would otherwise be 
degraded too quickly to be effective, face difficulties with effective local delivery or have 
undesirable side effects if administered systemically.  By utilizing these particles, chronic 




The goal of this study is to demonstrate that polyketal microparticles are effective as 
a drug delivery vehicle specified for pulmonary applications. To achieve this goal, as a 
proof of principle, a representative therapeutic was chosen to encapsulate within the 
polyketal microparticles that could have promise in the treatment of a chronic lung 
disease. The small hydrophilic peptide, Ac-SDKP, which has been shown to have anti- 
fibrotic properties in heart and kidney tissues, was ideal due to its potential to combat the 
currently untreatable pulmonary fibrosis (Yang, F., et al. 2004). To assess the value of 
polyketals as a drug delivery vehicle our study included three objectives. 1) Synthesize 
porous 10-20 um or non-porous 1-3 um particles with low polydispersity. 2) Optimize the 
load of the representative therapeutic, Ac-SDKP, in the polyketal microparticles to levels 
that will translate to reasonable clinical dosing concentrations. 3) Determine the 
biocompatibility of the polyketal particles in the lung using a murine model. 
       
1.3 Hypothesis 
Our central hypothesis is that polyketal particles do not elicit a significant 
inflammatory response in the lung and can be synthesized and optimally loaded with the 











2.1 Inadequacies of Current Chronic Lung Disease Treatments 
 Symptoms commonly associated with chronic lung diseases such as labored 
breathing and low blood oxygen levels are attributable to the pathological alterations of 
normal pulmonary structures.  COPD, BPD, and pulmonary fibrosis all have a unifying, 
salient feature of exhibiting inflammation followed by deposition of fibrotic tissue or 
scars. The initiation of inflammatory responses may vary among disease states and 
includes triggers such as environmental irritants, ventilator injury, genetic cues, or is 
simply idiopathic (Crouch 1990). However, as inflammation facilitates fibrosis, all can be 
histologically characterized by excessive extra cellular matrix (ECM) deposition largely 
due to increased fibroblastic proliferation (Gay, S.E., et al. 1998). The exact mechanism 
of the accumulation of fibrotic tissue has not been fully elucidated, but it is clear that this 
pathological remodeling response to lung injury is the source of compromised pulmonary 
functionality. Clinical management of these lung disorders has generally been ineffective 
at addressing the source of pulmonary dysfunction.  The efficacy of bronchodilators and 
corticosteroids in COPD and pulmonary fibrosis has been extremely limited (Barnes 
2000). Furthermore, systemic use of these agents leaves patients vulnerable to side 
effects such as brittle bones, cataracts, immunosuppression, tachycardia, and muscle 
tremors. A therapeutic that addresses the abnormal ECM framework has yet to be 
discovered, which presumably would lead to optimal lung function. 
 Since many chronic lung diseases are progressive, a potent therapeutic scheme 
necessitates non-invasive, directed administration. For disease states involving a long-
term surplus of ECM accumulation resulting in fibrosis, such therapies would be 





fibroblasts, cells primarily responsible for ECM production, are in a heightened 
proliferative state.  In addition, the ECM within established fibrotic scars is not as readily 
degraded as normal ECM. The combination of these phenomena leads to the chronic 
and progressive nature of these disease states. This highlights the pertinence of the 
development of therapies locally and non-invasively dispensed, so that the treatment 
maintains efficacy and longevity while minimizing side effects. 
 
2.2 Polyketal Microparticle Benefit in Pulmonary Drug Delivery 
With insufficient current treatments for chronic fibrotic lung disorders, an optimal 
treatment strategy is delivery of a therapeutic capable of retarding disease progression, 
without exacerbating the inflammatory response. Polymeric microparticles have been 
explored as a platform to non-invasively direct treatments to the lung interstitium. 
However, certain design criteria must be achieved in order for microparticles to be a 
viable option for lung drug delivery. Sized in the range of 1-3 um or 10-20 um for porous 
microparticles, these biomaterials have the potential to be inhaled comfortably by a 
patient from a dry powder spinhaler (Edwards, D.A., et al 1997). Once inhaled, the drug-
encapsulated microparticles will be deposited in the alveolar regions of the lung (Arnold, 
M.M., et al. 2007). The therapeutic potency can be further maximized through 
encapsulation in microparticles with short half-lives and excellent biocompatibility. This 
type of delivery allows for multiple, patient controlled, sustained administrations of 
treatment, which may prove beneficial in combating the progressive nature of these lung 
diseases.  
Presently, use of micoparticles as delivery vehicles to the lung have failed due to 
inadequacies of current biomaterials to be both aerosolizable and biocompatible. Ideally, 
microparticles are composed of hydrophobic polymers in order to prevent particle 





biocompatible materials such as alginate are not suitable for drug delivery because its 
hydrophilicity leaves it prone to aggregation. Another polymer, PLGA (Poly (dl- 
lactide/glycolide)), while hydrophobic and possessing structural properties necessary to 
form aerosolized particles, has been shown to elicit significant inflammatory responses. 
Previous studies in hamsters have demonstrated PLGA’s poor biocompatibility in the 
lung.  Results indicated that following a 1 mg intratracheal dose of 1-2.4 um PLGA 
micoparticles, macrophage populations increased 8 fold and neutrophil infiltration 
amplified by a factor of 20 within 24 hrs. Coupled with this, increased lymphocyte influx 
required 10 days to subside (Springer, C., et al. 2005). PLGA’s acidic degradation 
products perpetuate activation of immune and inflammatory cells. Upon PLGA 
hydrolysis, pH values can reach as low as 2-3, which not only exacerbates inflammation, 
but can potentially destabilize encapsulated biomolecules and/or catalyze inadvertent 
reactions (Houchin, M.L. et al. 2006). Another, undesirable property of PLGA is its 
extended half-life of approximately 40 days. Slow degradation of the particles impedes 
the release of active therapeutic and particle accumulation would preclude possibilities 
of frequent dosing (Dailey, L.A., et al. 2006). This would likely thwart the capabilities of 
the delivered drug to combat the persistent progression of these lung abnormalities.  
However, a new polymer has emerged that possesses promise in addressing 
challenges encountered by other polymer formulations. Polyketal polymers were 
developed based on an acetal exchange reaction (Lee, S., et al. 2007), which results in 
a polymer structure containing a ketal linkage in its backbone (Heffernan, M.J. and N. 
Murthy 2005). Such a chemical structure generates the benign hydrolysis products, 
acetone and diols. Acetone and diols are both neutral byproducts in contrast to PLGA’s 
acidic degradation products, which should not induce a significant inflammatory 
response. According to preliminary studies, polyketal microparticles injected at high 





activation is further reduced by the short 2-day half-life of certain polyketals at pH 4.5. 
Degradation products are membrane permeable, which will facilitate timely clearance 
from the lung following phagocytosis. This property will allow for frequent, multi-coursed 
therapies because particles should not accumulate in the lung in contrast PLGA 
particles. In addition, polyketals are hydrophobic and therefore possess the traits 
necessary to resist aggregation permitting aerodynamic properties to remain optimal for 
inhalation. 
Polyketal formulations are versatile and polymer properties such as hydrolysis 
rates can be manipulated to address specified applications. Previously, two other 
formulations of polyketals have been investigated for drug delivery, poly-(1,4-
phenyleneacetone dimethylene ketal) (PPADK) and poly(cyclohexane-1,4-diyl acetone 
dimethylene ketal) (PCADK).  However, these polyketals are not ideal for lung delivery 
and treatment of fibrotic disorders. PPADK has a rapid half-life of 35 hours at pH 5, but 
degrades into toxic aromatic byproducts (Heffernan, M.J. and N. Murthy 2005). PCADK 
has superior biocompatibility, but a long half-life of 24 days at pH 4.5 (Lee, S., et al. 
2007). Based on PCADK’s established biocompatibility, for the present study a PCADK 
derivative was used called PK3. This formulation exhibits a vastly decreased half-life of 2 
days at pH 4.5, while maintaining biocompatibility. PK3 is comprised of 87 mole% 
cyclohexane dimethanol and 13 mole% pentane diol and possesses many of the 
attributes required to be an effective carrier of therapeutics for pulmonary applications. 
 
2.3 Ac-SDKP Potential As an Anti-fibrotic Agent For Chronic Lung Diseases 
The exact mechanisms governing excess ECM deposition and the pathological 
remodeling of pulmonary structures observed with many chronic lung disorders remains 
unknown. However, key factors have been identified that significantly influence the 





the Transforming Growth Factor-beta (TGF-ß) signaling cascade may be the crux of 
these fibrotic pathologies (Gauldie, J., et al. 2007). The vast majority of TGF-ß exists in 
an inactive form and is bound to the latency-associated protein (LAP). Once TGF-ß is 
activated (partially or fully) by chemical or mechanical detachment of LAP, it is free to 
assert action upon its cell surface receptors. TGF-ß type I and II receptors following 
stimulation, initiate an intercellular signaling cascade that leads to the phosphorlation of 
the receptor activated Smads, smad 2 and 3. Phosphorlated smad 2/3 then complex 
with smad 4 and proceed to translocate to the nucleus where they direct gene 
expression as transcription factors (Gauldie, J., et al 2007). Many of the downstream 
effects of TGF-ß activation include the production and secretion of ECM proteins 
(Verrecchia, F. and A. Mauviel 2004) as well as alveolar epithelial to mesenchymal cell 
transition, which has been proposed to increase the number of ECM secreting cells 
(Kasai, H., et al. 2005). In pathological states involving fibrosis this pathway appears to 
be over activated and uncontrolled leading to increased deposition of ECM, which 
consequently stiffens the lung and promotes dysfunction. Animal models of pulmonary 
fibrosis have demonstrated that TGF-ß mRNA is upregulated in macrophages, which 
after secretion likely inundates the TGF-ß cascade resulting in eventual fibrotic effects 
(Higashiyama, H., et al. 2007). However, present studies indicate that prevention of 
some fibrotic models can be achieved by utilizing function-blocking antibodies against 
TGF-ß or soluble decoy TGF-ß receptors (Scotton, C.J. and R.C. Chambers 2007). 
Based on these results, it appears that a promising therapeutic would target disruption of 
the TGF-ß signaling pathway. 
Recently, the endogenous peptide seryl-lysyl-aspartyl-proline (SDKP), has been 
investigated as an anti-fibrotic agent potentially capable of regulating over activated 
TGF-ß responses. SDKP is the proteolytic byproduct of thymosin ß4 (Cavasin, M.A., et 





regulation of systemic blood pressure as it is readily degraded by angiotenisin converting 
enzyme (Azizi, M., et al. 1997).  In addition, SDKP has been shown capable of arresting 
some cells such as fibroblasts and hematopoietic stem cells in the S-phase, therefore 
halting proliferation (Rhaleb, N.E., et al 2001, Cashman, J.D.et al. 1994). Other studies 
have revealed that decreased levels of circulating SDKP initiate multi organ fibrosis 
(Cavasin, M.A., et al. 2007) while administration of SDKP post-infarct diminishes 
inflammation and fibrotic tissue accumulation absent of adverse blood pressure effects 
(Yang, F., et al. 2004). On the protein level, SDKP further exhibits anti-fibrotic effects 
through inhibition of endothelin1 facilitated collagen expression (Rhaleb, N.E., et al 
2001). Even more relevant are the indications that SDKP elicits an efflux of smad 7 from 
the nucleus, resulting in interference of the TGF-ß signaling cascade. Specifically, smad 
7 acts as a regulator and complexes with smad 2/3 preventing it from associating with 
smad 4. Without smad 4 association, gene transcription due to TGF-ß signaling through 
the smad pathway is diminished (Kanasaki, K., et al. 2006). SDKP has been shown to 
inhibit fibrotic events through multiple pathways on the nuclear, protein and organismal 
levels. Therefore, its use for treatment of chronic lung diseases characterized by fibrosis 
has great potential. 
 
2.4 Conclusion 
Current treatments of many chronic lung diseases have remained futile, failing to 
address the root of lung dysfunction. Typical approaches include the use of 
bronchodilators and corticosteroids, which do little to combat pathologies characterized 
by significant fibrosis.  Thus far, administration of potential therapeutics has been 
restricted to oral supplements, intravenous routes, or medications capable of achieving 
an inhalable form.  However, by utilizing polymeric micoparticles as a drug delivery 





through simple inhalation. Polyketal microparticles, more specifically PK3, have been 
shown to exhibit properties attuned with pulmonary drug delivery such as 
biocompatibility and short half-lives.  They have the capacity to encapsulate a variety of 
biomolecules such as siRNA, enzymes, oligo nucleotides and small peptides that could 
be investigated for efficacy in treating pulmonary complications. In this study, PK3’s 
viability as a pulmonary drug delivery vehicle was assessed using the model therapeutic 
Ac-SDKP.   Ac-SDKP, from previous studies, asserts an anti-fibrotic effect through the 
disruption of the TGF-ß signaling cascade, which is an established facilitator of 
pulmonary fibrosis. By determination of biocompatibility and optimization of 
encapsulation of this model drug, PK3 microparticles have the potential to reveal novel 
therapeutic avenues that address the inadequacies of present clinical treatments of 

























Ideally, effective therapeutic carriers for pulmonary applications can be efficiently 
loaded with a target therapeutic, while maintaining specified size constraints. The 
synthesized particles should display low polydispersity and sizes in the range of 1-3 um 
for non-porous particles and 10-20 um for porous particles (Cryan, S.A 2005, Sung, J.C. 
2007). These size constraints ensure drug release is uniform and preservation of 
aerodynamic properties. Preliminary studies indicate that non porous particles ranging 
from 0.5–4.14 um can be effectively aerosolized and dispersed, which is necessary for 
particle inhalation. In addition, optimal Ac-SDKP loading will minimize the eventual 
particle dosing required for clinical applications of the therapeutic and concurrently 
minimize the risk of inflammatory or immune responses due to the particles. 
In an effort to satisfy the prescribed particle design criteria, various double 
emulsion particle synthesis techniques were evaluated according to the drug load 
efficiency and particle size distribution. Double emulsions are essential for encapsulation 
of hydrophilic molecules (e.g. Ac-SDKP) within hydrophobic polymers (e.g. PK3) due to 
the low affinity the peptide has for the polymer. The basic water in oil in water (w/o/w) 
double emulsion technique involved solubilizing the peptide within a surfactant 
containing solution such as poly vinyl alcohol (PVA), which increased the peptide’s 
probability of interaction with the polymer. Then emulsifying the peptide solution within 
an organic solution containing PK3 yielded the primary emulsion. After which, a more 
concentrated surfactant solution was added to the primary emulsion and subsequently 
emulsified again. This caused the PK3 to form microspheres encompassing the 





particle suspension, the microparticles were allowed to harden and stabilize. At this 
stage, microparticles were washed free of PVA and dried by lyophilization. 
We altered various parameters in this basic w/o/w double emulsion synthesis 
technique in an attempt to address our objective of optimally loading Ac-SDKP within 
polyketal particles. First, the emulsion apparatus of both the primary and secondary 
emulsion were varied with the goal of controlling particle size distribution without 
diminishing drug load efficiency. The rationale was that the more rigorous the agitation 
process, the smaller and narrower the size distribution of the resulting particles.  
Secondly, the effect of the outer aqueous phase (i.e. the surfactant solution of the 
secondary emulsion) pH was investigated. Based on previous work, a pH similar to the 
isoelectric point (pI) of the drug of interest increased load efficiency (Peltonen 2004).  
For Ac-SDKP, the pI is approximately 5.55 and when exposed to solutions of this pH the 
peptide maintains a neutral charge, which should facilitate its encapsulation within the 
hydrophobic polyketal.  Thirdly, the drug to polymer ratio of the initial formulation was 
altered in an effort to increase load efficiency. Studies, based on work by Peltonen et al., 
have indicated that using minimal drug to polymer ratios promote optimal drug 
encapsulation (Peltonen 2004). 
 In addition to the aforementioned parameter perturbations, we further 
modified the double emulsion by utilizing a cryo w/o/w emulsion and a solid in oil in 
water emulsion (s/o/w). The cryo w/o/w emulsion method involved freezing the primary 
emulsion before performing the secondary emulsion. This method attempted to slow the 
release of the peptide into the outer aqueous phase due to the peptide’s frozen state at 
the commencement of the secondary emulsion. Theoretically, this method will increase 
drug entrapment within formed microparticles. The s/o/w technique capitalized on the 
peptide’s insolubility in organic solvents. After solid peptide dispersion within the primary 





occur, it must first dissolve in the aqueous phase.  The lengthened time required to 
solubilize the peptide permits the peptide to remain in the organic phase longer and thus 
increases the likelihood a polymeric microparticle will encapsulate the peptide.  
After optimally loading microspheres, we further characterized the particles by 
assessing preservation of the encapsulated therapeutic’s bioactivity. From this 
assessment we determined the effect processing these loaded microparticles has on the 
capacity of Ac-SDKP to function as an anti-fibrotic agent.  Previous studies have 
established that Ac-SDKP, administered in vitro, can down regulate TGF-ß induced 
Fibronectin (FN) mRNA expression (Guo et al. 2004, Hocevar et al.1999). Therefore, by 
stimulating cells with TGF-ß to promote FN expression and subsequently treating cells 
with Ac-SDKP loaded particles, bioactivity can be quantitatively compared by resultant 
FN mRNA levels. By systematically exploring the effects of these specified particle 




PK3 polymer (generously donated by Murthy lab), Ac-SDKP peptide (Genscript, 
Piscataway, NJ), fluorescamine (MP Biomedicals, Solon, OH), acetone (VWR 
International, Suwanee, GA), chloroform (EMD Chemicals, Cincinnati, OH), polyvinyl 
alcohol (Aldrich, St. Louis, MO), diochloromethane (ACROS, Geel, Belgium), hexane 
(ACROS, Geel, Belgium), primary rat lung Sprague Dawley (RLSD) fibroblasts (isolated 
by Ashley Carson), Dulbecco’s Modification of Eagle’s Media (Mediatech, Herndon, VA), 
Fetal Bovine Serum (Mediatech, Herndon, VA), Penicillin-Streptomycin (Mediatech, 
Herndon, VA), RNeasy Kit (Qiagen, Valencia, CA), Power SYBR Green I RNA to Ct Kit 
(Applied Biosystems, Foster City, CA), Fibronectin qPCR primers (Invitrogen, Frederick, 





3.2.2 Ac-SDKP Loaded PK3 Particle Synthesis Optimization 
3.2.2.1 Basic Double Emulsion Technique 
Ac-SDKP peptide (5 mg) was dissolved in 50 ul of a 1% (v/v) polyvinyl alcohol 
solution (PVA) at pH 8.5 to yield a 100 mg/ml peptide solution. The peptide solution was 
added to an 8 ml glass vial. In a separate 8 ml glass vial, 50 mg of PK3 was dissolved in 
500 ul of dichloromethane (DCM) to also yield a 100 mg/ml solution. The PK3 in DCM 
solution was then added to the Ac-SDKP peptide solution and emulsified with a probe 
sonicator for 30 sec (output 20W). Immediately, 5 ml of a 5% PVA buffered (pH 6.8) 
solution was added to this primary emulsion and homogenized (level 2) for 1.5 min 
yielding the secondary emulsion. The emulsion was added to a 100 ml round bottom 
flask and DCM was removed with the use of a Rotovap. The flask was rotated at speed 
3 for the duration of the evaporation process, which included cycling the mixture 
between low and high pressures over the course of approximately 10-15 min. Contents 
of the 100 ml round bottom flask (particle suspension) were then dispensed into a 15 ml 
conical tube and diluted with deionized water to approximately 10 ml.  A 1 ml aliquot of 
the particle suspension was reserved for dynamic light scattering analysis to determine 
particle size distributions.  The particle suspension was centrifuged for 10 min at 6000xg. 
The supernatant was removed and particles resuspended by vortexing with 10 ml of 
fresh deionized (DI) water to remove PVA. Centrifugation was repeated. The 
supernatant was again removed and the particles resuspended with fresh DI water. The 
suspension was then frozen for approximately 45 min at -80 C. The frozen particle 
suspension was lyophilized overnight. 
 
3.2.2.2 Emulsion Apparatus Optimization 
The particle synthesis was performed according to the previous basic technique 





secondary emulsions. Perturbations of the parameters are listed below (Table 1). Three 
experiments were performed and the basic particle synthesis technique conditions as 
detailed previously are highlighted in blue. 
 
Table 1. Emulsion Devices. 
 
Exp’t. No. Primary Emulsion Secondary Emulsion 
 Device Time Device Time 
A1 Sonicator  
 





90 sec Vortex 
(3000 rpm) 
120 sec 





3.2.2.3 Outer Aqueous Phase pH Optimization. 
The particle synthesis was performed according to the previous basic technique 
protocol with the exception of varying the outer aqueous phase pH (i.e. the pH of the 5% 
(v/v) PVA solution of the secondary emulsion). Perturbations of the parameters are listed 
below (Table 2). Four experiments were performed and the basic technique conditions 
are highlighted in blue. 
 
Table 2. pH of Outer Aqueous Phase. 













3.2.2.4 Drug to Polymer Ratio Optimization 
The particle synthesis was performed according to the previous basic technique 
protocol with the exception of varying the drug to polymer ratio in the initial formulation. 
Perturbations of the parameters are listed below (Table 3). Two experiments were 
performed and the basic technique conditions are highlighted in blue. 
 
Table 3. Drug to Polymer Ratio. Note: Basic technique experimental conditions were 
not performed again. 
 
Exp’t. No. SDKP: PK3 
Basic Tech. 10% (add 50 ul of 100 mg/ml SDKP) 
C1 5% (add 25 ul of 100 mg/ml SDKP) 




3.2.3 Ac-SDKP Loaded Porous Particle Synthesis 
 A particle synthesis technique ensuring the fabrication of porous particles was 
performed. In a 4 ml glass vial, 15 mg of Ac-SDKP peptide was dissolved in 150 ul of 1% 
(v/v) PVA pH 8.5 resulting in a 100 mg/ml peptide solution. Then in an 8ml glass vial, 
150 mg of PK3 was in dissolved in 1375 ul of DCM + 225 ul of hexane by vortexing and 
heating.  The 100 mg/ml Ac-SDKP solution was pipetted into the bottom of the 8 ml 
glass vial containing the PK3, DCM, and hexane. This mixture was homogenized for 1.5 
min. at speed 5 yielding the primary emulsion. Next, this primary emulsion was pipetted 
into the bottom of 20 ml of a 5% (v/v) PVA (buffered). This mixture was again 
homogenized for 1.5 min, at speed 2.  Immediately, this secondary emulsion was poured 
into 80 ml of 1% (v/v) PVA.  The resulting mixture was placed on the Rotovap in a 500 
ml round bottom flask to the remove the organic solvents. The flask was rotated at 
speed 3 without heat for 15 min to remove the DCM.  Subsequently, the flask was 





30 min to remove the hexane. After the organic solvent removal, a 1 ml aliquot of the 
particle suspension was reserved for dynamic light scattering (DLS) analysis. The 
remainder of the particle suspension was divided into two 50 ml conical tubes. The 
suspensions were then centrifuged at 8000xg for 10 min. The supernatant was removed 
and particles resuspended by vortexing with 10 ml of fresh deionized (DI) water to 
remove PVA. Centrifugation was repeated. The supernatant was again removed and the 
particles resuspended with fresh DI water. The suspension was then frozen for 
approximately 45 min at -80 C. Frozen particle suspension was lyophilized overnight. 
 
3.2.4 Solid in Oil in Water Double Emulsion 
Solid Ac-SDKP peptide (5 mg) was added to an 8 ml glass vial. In a separate 8 
ml glass vial, 50 mg of PK3 was dissolved in 400 ul of dichloromethane (DCM) and 100 
ul ethyl acetate to also yield a 100 mg/ml solution. The PK3 in DCM/ ethyl acetate 
solution was then added to the solid Ac-SDKP peptide and emulsified with a probe 
sonicator for 30 sec (output 20 W). Immediately, 5 ml of a 5% PVA buffered (pH 6.8) 
solution was added to this primary emulsion and homogenized (level 3) for 1.5 min 
yielding the secondary emulsion. The emulsion was added to a 100 ml round bottom 
flask and DCM was removed with the use of a Rotovap. The flask was rotated at speed 
3 for the duration of the evaporation process, which included cycling the mixture 
between low and high pressures over the course of approximately 10-15 min. Contents 
of the 100 ml round bottom flask (particle suspension) were then dispensed into a 15 ml 
conical tube and diluted with deionized water to approximately 10 ml.  A 1 ml aliquot of 
the particle suspension was reserved for dynamic light scattering analysis to determine 
particle size distributions.  The particle suspension was then centrifuged for 10 min at 
6000xg. The supernatant was removed and particles resuspended by vortexing with 10 





supernatant was again removed and the particles resuspended with fresh DI water. The 
suspension was then frozen for approximately 45 min at -80C. Frozen particle 
suspension was lyophilized overnight. 
 
3.2.5 Cryo Water in Oil in Water Double Emulsion 
Ac-SDKP peptide (5 mg) was dissolved in 50 ul of a 1% (v/v) polyvinyl alcohol 
solution (PVA) at pH 8.5 to yield a 100 mg/ml peptide solution. The peptide solution was 
added to an 8 ml glass vial. In a separate 8 ml glass vial, 50 mg of PK3 was dissolved in 
500 ul of dichloromethane (DCM) to also yield a 100 mg/ml solution. The PK3 in DCM 
solution was then added to the Ac-SDKP peptide solution and emulsified with a probe 
sonicator for 30 sec (output 20W). Then this primary emulsion was frozen completely in 
a dry ice/ acetone mixture. Immediately after freezing, 5 ml of a 5% (v/v) PVA buffered 
(pH 6.8) solution was added to this primary emulsion and homogenized (speed 3) for 1.5 
min yielding the secondary emulsion at room temperature. The emulsion was added to a 
100 ml round bottom flask and DCM was removed with the use of a Rotovap. The flask 
was rotated at speed 3 for the duration of the evaporation process, which included 
cycling the mixture between low and high pressures over the course of approximately 
10-15 min. Contents of the 100 ml round bottom flask (particle suspension) were then 
dispensed into a 15 ml conical tube and diluted with deionized water to approximately 10 
ml.  A 1ml aliquot of the particle suspension was reserved for dynamic light scattering 
analysis to determine particle size distributions.  The particle suspension was 
centrifuged for 10 min. at 6000xg. The supernatant was removed and particles 
resuspended by vortexing with 10 ml of fresh deionized (DI) water to remove PVA. 
Centrifugation was repeated. The supernatant was again removed and the particles 
resuspended with fresh DI water. The suspension was then frozen for approximately 45 





3.2.6 Peptide Detection: Fluorescamine Assay Standard Curve 
Ac-SDKP was diluted with PBS to the following concentrations starting with a 5 
mg/ml stock solution: 100, 70, 50, 30, 10, 1, and 0 ug/ml.  Each concentration of peptide 
(150 ul) was added to a black 96 well fluorescent microplate in triplicate. At the start of 
the assay, 50 ul of fluorescamine solution (3 mg/ml in acetone) was added to each well 
using a multichannel pipettor and measures were taken to protect the fluorescamine 
from light. The microplate was shaken by the plate reader for 45 sec. Fluorescamine 
reacts with primary amines (e.g. lysine on Ac-SDKP) and resultant product emits a 
detectable fluorescent signal at 460 nm when excited at 400 nm. Resultant fluorescence 
values were recorded.  
 
3.2.7 Liquid-Liquid extraction technique verification 
A specified amount of 1000 ug/ml (40, 20, 5, and 0.5 ul) of Ac-SDKP in PBS was 
added to 200 ul of chloroform in a 1.5 ml Eppendorf tube. The mixture was then vortexed 
rigorously for 30 sec. PBS (500 ul) was added to the Ac-SDKP/chloroform mixture. The 
mixture was again vortexed for 30 sec.  In addition the mixture was further agitated by 
pipetting the aqueous phase through the organic phase and subsequently the organic 
phase through the aqueous phase.  The mixture was then allowed to phase separate. 
The aqueous phase (470 ul) was removed from the mixture.  Then 150 ul of the aqueous 
phase was place in a black 96 well fluorescence microplate in triplicate including 3 wells 










3.2.8 Ac-SDKP Particle Load Determination Technique Validation 
Four different techniques were tested to ensure complete peptide release from 
particles and extraction from the organic phase. Particles used were from the same 
synthesis batch. 
 
3.2.8.1 Method 1: rigorous agitation, emulsion droplets present 
Approximately 1 mg of Ac-SDKP loaded particles was dissolved in 200 ul of 
chloroform in a 1.5 ml Eppendorf tube. The mixture was vortexed rigorously for 20 sec 
and 500 ul of PBS was then added to the mixture. Again the mixture was vortexed 
rigorously for and additional 10 min resulting in an emulsion. The emulsion was then 
phase separated partially, with emulsion droplets still visible. The aqueous phase (470 
ul) was carefully removed and transferred to a second Eppendorf tube. Then 150 ul of 
the aqueous phase was placed in a black 96 well fluorescence microplate in triplicate 
including 3 wells of a PBS blank. Ac-SDKP was detected and quantified per the 
fluorescamine assay protocol. 
 
3.2.8.2 Method 2: gentle agitation, emulsion droplets absent 
Approximately 1 mg of Ac-SDKP loaded particles was dissolved in 200 ul of 
chloroform in a 1.5 ml Eppendorf tube. The mixture was vortexed rigorously for 20 sec 
and 500 ul of PBS was then added to the mixture. Then the mixture was vortexed gently 
for 10 sec and the tube inverted several times. The mixture was allowed to phase 
separate completely (i.e. no emulsion droplets present). Further agitation was achieved 
by pipetting the aqueous phase through the organic phase and subsequently the organic 
phase through the aqueous phase. The aqueous phase (470 ul) was carefully removed 





place in a black 96 well fluorescence microplate in triplicate including 3 wells of a PBS 
blank. Ac-SDKP was detected and quantified per the fluorescamine assay protocol. 
 
3.2.8.3 Method 3: rigorous agitation, emulsion droplets absent 
Approximately 1 mg of Ac-SDKP loaded particles was dissolved in 200 ul of 
chloroform in a 1.5 ml Eppendorf tube. The mixture was vortexed rigorously for 20 sec 
and 500 ul of PBS was then added to the mixture. Again the mixture was vortexed 
rigorously for and additional 10 min resulting in an emulsion. The emulsion was then 
phase separated completely by centrifugation and pipetting. The mixture was centrifuged 
at 5000 rpm for 2 min and/or pipetted repeatedly until there was distinctive separation 
between the organic and aqueous phases. The aqueous phase (470 ul) was carefully 
removed and transferred to a second Eppendorf tube. Then 150 ul of the aqueous phase 
was placed in a black 96 well fluorescence microplate in triplicate including 3 wells of a 
PBS blank. Ac-SDKP was detected and quantified per the fluorescamine assay protocol. 
 
3.2.8.4 Method 4: gently agitation, emulsion droplets present 
Approximately 1 mg of Ac-SDKP loaded particles was dissolved in 200 ul of 
chloroform in a 1.5 ml Eppendorf tube. The mixture was vortexed rigorously for 20 sec 
and 500 ul of PBS was then added to the mixture. Then the mixture was vortexed gently 
for 10 sec and the tube inverted several times. The mixture was allowed to phase 
separate partially (i.e. some emulsion droplets present). The aqueous phase (470 ul) 
was carefully removed and transferred to a second Eppendorf tube. Then 150 ul of the 
aqueous phase was placed in a black 96 well fluorescence microplate in triplicate 
including 3 wells of a PBS blank. Ac-SDKP was detected and quantified per the 






3.2.9 Ac-SDKP Particle Load Determination 
Based on results from Particle Load Determination Technique Validation, method 
3 was chosen as the standard load determination technique. This technique includes 
rigorous agitation and complete resolution of formed emulsion. 
 
3.2.10 Peptide Release From Particles 
 Peptide release from particles exposed to a neutral pH was determined at a 
single time point. A time course of peptide release was not determined due to the 
insensitivity of the peptide detection assay. Approximately 2 mg of Ac-SDKP loaded 
particle was added to 1 ml PBS (pH 7.3). The particle suspension was incubated at 37 C 
and simultaneously agitated horizontally at 80 rpm. After 76 hrs, a 0.8 ml aliquot was 
removed and centrifuged at 14,000 rpm for 15 min.  Ac-SDKP supernatant content was 
quantified using the fluorescamine assay. 
 
3.2.11 Dynamic Light Scattering (DLS) Analysis 
Dynamic light scattering is a technique that detects laser light scattering due to 
interference by small particles.  The pattern of light scatter can be correlated to particle 
size distributions. During the particle synthesis process after solvent removal, but before 
particle washing an aliquot of particle suspension was reserved for DLS analysis. The 
particle suspension (1 ml) was placed in a clear plastic cuvett and diluted with DI water 
up to full cuvette capacity. Readings were taken over 1 min at 25 C to determine the 
particle effective diameter and particle size distributions. 
 
3.2.12 Scanning Electron Microscopy (SEM) 
Using a Hitachi S-800 SEM, high-resolution images were obtained of the 





mm pin type SEM mounts. Small amounts of particles were then spread across the 
topside of the carbon tape. Adhered particles were gold coated using a gold sputterer 
and imaged to visualize particle morphology. 
 
3.2.13 Ac-SDKP Loaded Particle Bioactivity Assay 
Ac-SDKP inhibition of TGF-ß induced FN expression was used as an 
assessment of peptide bioactivity (Gua 2004). RLSD primary fibroblasts were seeded at 
a density of 100,000 cells/well in a 12 well plate. Then the cells were allowed to recover 
and grow for 48 hrs in normal growth conditions (DMEM with 10% FBS, 1% 
penicillin/streptomycin). Next, we induced a state of cellular quiescence by placing cells 
in serum free DMEM media. After 24 hrs, cells were stimulated for 8 hrs according to the 
following treatments groups: 1) TGF-ß, 2) negative control (no treatment), 3) empty PK3 
particles, 4) TGF-ß with empty PK3 particles, 5) free Ac-SDKP, 6) loaded Ac-SDKP 
particles, 7) pre-extracted Ac-SDKP from loaded PK3 particles. TGF-ß was administered 
at a final concentration of 5 ng/ml, free and extracted Ac-SDKP at 100 nM, and particles 
at 55 ug/ml. After treatment, RNA was isolated using the RNeasy Mini Kit (Qiagen) per 
manufacturers’ instructions. Isolated RNA was quantified and assessed for purity by their 
260:280 and 230:280 absorbance ratios.  After which, quantitative real time polymerase 
chain reaction (qPCR) was performed to detect alterations of TGF-ß induced fibronectin 
expression. We used the Applied Biosystems Power SYBR Green I one-step RNA to Ct 
qPCR kit, which allows for cDNA synthesis and amplification in the same reaction 
vessel. Primer concentrations were 200 nM for both forward (5’-
GTGGCTGCCTTCAACTTCTC-3’) and reverse (5’-GTGGGTTGCAAACCTTCAAT-3’) 
fibronectin primers (Yoshida et al. 2002) and 400 nM for both forward and reverse of ß-
actin primers (Occam Biolabs). Forty ng of RNA template was used for each 20 ul 





Sequence Detector. Using RNA as a template, reverse transcription providing cDNA 
synthesis occurred at 48 C for 30 min. Then DNA polymerase was activated at 95 C for 
ten min.  DNA amplification occurred during 40 thermocycles at 95 C for 15 sec followed 
by 60 C for 1 min. A melt curve was obtained for each reaction after each qPCR run to 
ensure single product formation. 
 
3.3 Results 
3.3.1 Ac-SDKP Loaded PK3 Particle Optimization 
Various Ac-SDKP encapsulated PK3 particle synthesis techniques were 
investigated and optimized according primarily to Ac-SDKP load followed by particle size 
and polydispersity as summarized in Table 4. The w/o/w techniques designated as the 
“A series” evaluated the effect of the emulsion apparatus on particle analysis 
parameters. Upon initial assessment, the use of a sonicator and homogenizer for the 
primary and secondary emulsions respectively, yielded the highest Ac-SDKP loading at 
3.59%. However, the loading efficiency could not be replicated in successive trials. 
Considering particle size, trials utilizing a votexer as the secondary emulsion device 
resulted in particles unsuitable for aerosolization with effective diameters ranging from 
22- 42 um.  The influence of the outer aqueous phase pH (i.e. the pH of the secondary 
emulgent solution), denoted as the “B series,” resulted in a 6 fold increase in peptide 
loading at acidic pHs as compared to neutral. However, particle preparations at 5.3 and 
1.6 outer aqueous phase pH, displayed elevated, undesirable effective diameters of 27 
and 41 um respectively. We also examined the effect of the initial drug to polymer 
formulation on final Ac-SDKP load in the “C series.” Results indicated that a preliminary 
15% peptide to PK3 ratio was optimal, producing Ac-SDKP particle loads 0.1% above 






Given poor loading efficiencies and particle sizing from previous experimental 
perturbations, we further modified the particle synthesis technique despite trends of 
slight improvement.  To address the aerodynamic particle criterion, we performed a 
synthesis procedure ensuring fabrication of porous particles. Particle porosity widens the 
size constraint necessary to maintain aerodynamic properties. By dissolving the PK3 
polymer in a mixture of two organic solvents (hexane and DCM) with distinct vapor 
pressures, pores were formed during the solvent evaporation process.  Following the 
secondary emulsion, we first evaporated DCM and the microspheres hardened leaving 
some hexane entrapped within the particles. Subsequently, at a higher temperature and 
pressure, hexane vaporized and in the process created pores upon release from the 
particles. Although, the particle size and morphology were consistent with the 
aerosolization criterion, with a diameter of 8 um, the Ac-SDKP loading remained low 
(0.25%).  
In general the diminished Ac-SDKP loading may be attributed to loss during the 
final particle washing steps to remove the emulgent, PVA. Therefore, a 50% and 90% 
ethanol wash was performed. We attempted to interfere with Ac-SDKP loss to the 
aqueous wash due to the peptide’s decreased solubility in ethanol. The resultant particle 
load of 0.29% suggested that a 90% ethanol wash positively affected peptide loading, 
but particle size was not conducive for aerosolization due to the particle aggregation 
observed (Figure 3). A final variation on the w/o/w double emulsion was investigated.  
We performed a cryo w/o/w technique, which is essentially invariable to the basic w/o/w 
emulsion, but preceding the secondary emulsion we snap froze the primary emulsion. 
This was an effort to hinder peptide release into the outer aqueous phase of the 
secondary emulsion and promote drug entrapment due to the peptide’s frozen state. 
Evaluated Ac-SDKP particle loading and size achieved a similar value obtained by the 





 Lastly, we examined a solid in oil in water emulsion method. This procedure was 
similar to previous w/o/w emulsion, but disperses solid peptide within the organic phase 
during the primary emulsion. Upon commencement of the secondary emulsion with the 
addition of an emulgent solution followed by agitation, for peptide loss to occur, it must 
first dissolve into the aqueous phase. This lengthens the duration the peptide remains 
emulsified in the organic phase and the probability that a microsphere will entrap the 
peptide. The data demonstrates this method’s superiority for both maximizing Ac-SDKP 
loading while maintaining low particle sizes. Among independent replicate synthesis 
trials, peptide loading ranged from 0.48% to 1.93%, while particle sizes spanned 2.7 -5.5 
um across trials. The average polydispersity measurement was 0.293, which indicates a 
relatively narrow distribution of particle sizes. Narrow size distribution should promote 
uniform peptide release from particles upon hydrolysis. In an attempt to further increase 
Ac-SDKP loading both the cryo w/o/w and s/o/w methods were performed with 90% 

















Table 4. Characterization of SDKP Loaded PK3 Microparticles. Detailed descriptions 
of protocols for each particle synthesis trial and SDKP load determination are given in 
the methods section. A series: Emulsion device modified; A1: 1-sonicator, 2- 
homogenizer; A2: 1-homgenizer, 2-vortex; A3: 1-sonicator, 2-vortex. B series: Outer 
aqueous phase pH modified; B1, 6.8; B2, 11.5; B3, 5.3; B4, 1.6. C series: Drug to 
polymer ratio modified; C1: 5%; C2 15%. Etoh wash: particles washed with ethanol at 
concentration indicated to remove 5% PVA after solvent evaporation. Effective diameter 
and polydispersity were determined by DLS. All loading values are adjusted for 
background levels determined from empty polyketals. *Basic synthesis technique. 
Standard deviations reported for Ac-SDKP load determined more than once for the 



























*A1 replicate 1 3.59% 11.3 0.219 
*A1 replicate 2 -0.06% +0.01 6.0 0.243 
*A1 replicate 3 -0.02% +0.00 24.5 0.640 
A2 1.50% 22.2 0.302 
A3 0.13% +0.11 41.9 0.487 
*B1 0.04% +0.01 14.6 0.201 
B2 0.02% 33.4 0.475 
B3 0.25% +0.03 26.7 0.366 
B4 0.24% 40.6 0.524 
C1 0.05% +0.04 9.0 0.137 
C2 0.14% +0.08 10.8 0.256 
Porous 0.25% +0.09 8.6 0.118 
50% etoh wash -0.01% 15.7 0.212 
90% etoh wash 0.29% 20.7 0.283 
Cryo w/o/w 0.28% +0.06 17.8 0.646 
S/O/W replicate 1 0.48% +0.36 5.5 0.177 
S/O/W replicate 2 1.93% +0.24 2.7 0.388 
S/O/W replicate 3 1.20% +0.61 4.6 0.153 
Cryo w/o/w with 
90% etoh wash 
0.07% +0.11 19.9 0.285 
S/O/W with 90% 
etoh wash 





3.3.2 Ac-SDKP Peptide Detection: Fluorescamine Standard Curve 
An Ac-SDKP standard curve was generated using a fluorescence assay utilizing 
fluorescamine. Fluorescamine reacts with primary amines and consequently emits a 
detectable fluorescent signal at 460 nm when excited at 400 nm. Ac-SDKP has one free 
amine located on lysine and was quantified with acceptable precision and accuracy 
utilizing this assay. Three independent curves were created incorporating Ac-SDKP 
concentrations up to 100 ug/ml. After linear regression analysis, slopes obtained were 
11.254, 11.543, and 10.572 with respective R2 values of 0.9947, 0.9952, and 0.9976 
(Figure 1). For Ac-SDKP quantification in the peptide particle load determination, the 

























Figure 1. Ac-SDKP Standard Curve. The standard curve was generated using the 
fluorescamine assay. On the basis of this curve, concentrations of Ac-SDKP extracted 
from loaded PK3 particles were quantified. The above curve is representative of three 
independent curves generated. The remaining independent curves resulted in slopes of 
11.543 and 10.572 with R2 values of 0.9952 and 0.9976 respectively. The average slope 






















3.3.3 Liquid-Liquid Extraction Technique Validation 
 
 To ensure Ac-SDKP is not appreciably soluble in the organic phase (chloroform) 
used during peptide extraction from PK3 for particle load determinations, we validated 
the extraction technique. Rigorously mixing known concentrations of Ac-SDKP in 
chloroform and then extracting the peptide with the addition of an aqueous solution 
allowed a comparison between theoretical Ac-SDKP amounts introduced and the actual 
Ac-SDKP concentrations calculated by use of the fluorescamine assay. Concentrations 
of Ac-SDKP tested ranged from 1 to 80 ug/ml. In the lower concentration range, error 
remained within less than 10%. With high concentrations error was miniscule and was 
within 1% (Table 5). 
 
 
Table 5. Liquid-Liquid Extraction Technique Validation. A known concentration and 
amount of Ac-SDKP was subjected to the established extraction technique of the peptide 
from polyketals particles.  Various amounts of free Ac-SDKP were immersed and mixed 
in an organic solvent and subsequently extracted with the addition of an aqueous phase. 
The extraction protocol followed the previously detailed SDKP Load Determination as 






3.3.4 Ac-SDKP Particle Load Determination Technique Validation 
 To promote complete release of Ac-SDKP from synthesized particles, the rigor 
and procedure of extraction were investigated.  This ensures accurate determination of 
the Ac-SDKP loading in PK3 particles, so that optimal synthesis conditions can be 
Ac-SDKP Concentrations  
Theoretical (ug/ml) Actual (ug/ml) Percent Error 
40 39.60 0.98 
80 80.79 0.99 
10 9.03 9.60 





identified. We evaluated four distinct methods.  Method one involved rigorous agitation, 
allowing an emulsion to form. We partially resolved the emulsion and then removed the 
aqueous phase for quantification of Ac-SDKP by the fluorescamine assay. In method 
two, readings were obtained after gentle agitation with no emulsion formation. Method 
three again involved rigorous agitation, but included complete resolution of the formed 
emulsion by centrifugation. Lastly, in method four after gentle agitation and the presence 
of emulsion droplets, Ac-SDKP was quantified. Using particles obtained from the same 
synthesis batch, method three yielded the most detectable peptide at 0.24% loading 
(Table 6).  This 2.6 fold increase above method 1, suggests that for maximal peptide 
extraction from PK3 and the organic phase, rigorous agitation to the point of emulsion 
formation followed by complete resolution is needed. 
 
Table 6. Ac-SDKP Particle Load Determination Technique Validation. Varying 
methods of a liquid-liquid extraction technique were performed to promote maximal Ac-
SDKP peptide release from the loaded PK3 particles and the organic phase. In depth 
descriptions of techniques are provided in the methods section. Method 1: rigorous 
agitation, emulsion droplets present. Method 2: gentle agitation, emulsion droplets 
absent. Method 3: rigorous agitation, emulsion droplets absent. Method 4: gentle 




3.3.5 Peptide Release From Particles 
 By incubating and agitating a 2 mg/ml Ac-SDKP loaded particle suspension, we 
obtained a measure of peptide release from PK3 particles.  After 76 hrs of incubation at 
37 C, the suspension supernatant was tested for Ac-SDKP content and compared to 
peptide loading as determined by liquid-liquid extraction.  We found that by 76 hrs in 
Method SDKP Loading (w/w) 








PBS (pH7.3), 92% of encapsulated peptide was released. This indicates rapid particle 
hydrolysis. In vivo, this property will promote effective therapeutic dissemination as well 
as timely clearance of degraded byproducts. 
 
3.3.6 Particle Morphology Characterization 
After determination of Ac-SDKP particle loading from various synthesis trials, 
Scanning Electron Micrographs were captured for methods yielding increased peptide 
loading.  Visualization enables assessment of particle integrity and the uniformity of 
particle morphology. For the “A series,” we verified particle formation due to the 
stringency disparities among emulsion devices. A1, which utilized a sonicator and 
homogenizer for the primary and secondary emulsions respectively yielded rough, but 
consistent particles. The trial utilizing a sonicator for the first emulsion and vortex for the 
second (A3), demonstrates successful particle formation, but with a significant 
population of large particles. However, for A2 (homogenizer- first emulsion; vortex- 
second emulsion), despite high Ac-SDKP loading at 1.5%, inconsistent and low particle 
formation was observed.  From this, we can ascertain that a sonicator is necessary for 
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Figure 2. SEM of A Series Particles. Scanning Electron Micrographs taken of  A series 
particle synthesis techniques. The A series varied the emulsion devices used for both 
the primary and secondary emulsions. Emulsion device modified; A1: 1-sonicator, 2- 














The three s/o/w replicates yielding a high Ac-SDKP load were also imaged. 
Micrographs illustrate successful, consistent particle synthesis and relatively low 
polydispersity. However, surface morphology does appear variable among the trials. 
This is due to the use of different PK3 polymer batches, which inevitably possess 
variance. Other results do not indicate any further affect on particles due to PK3 
inconsistency.  In addition, the s/o/w trial with a 90% ethanol wash was visualized. 
Images suggest that ethanol is incompatible with PK3 and effectively damages particle 



















          
                    Replicate 1                                                    Replicate 2 
 
  Replicate with 90% ethanol wash 
Figure 3. SEM of S/O/W Particles: Replicate Trials. Scanning Electron Micrographs 
taken of the solid in oil in water emulsion technique particles synthesized. Three 
independent replicate trials were performed and imaged. A detailed description of the 











3.3.7 Ac-SDKP Biochemical Activity After Release From Particles 
Following Ac-SDKP encapsulation within PK3 microparticles, we evaluated the 
preservation of the entrapped peptide’s bioactivity. This determination is essential to 
verify maintenance of Ac-SDKP’s anti-fibrotic properties. Previous work indicates that 
Ac-SDKP effectively reduces TGF-ß induced fibronectin mRNA expression (Guo et al. 
2004, Hocevar et al.1999). By stimulating primary rat fibroblasts with TGF-ß and 
simultaneously subjecting the cells to various particle and Ac-SDKP treatments, we 
elucidated particle processing effects on Ac-SDKP bioactivity.  
Fibronectin (FN) mRNA levels were quantified via qPCR.  To assess relative 
changes in FN expression due to experimental treatments, we utilized the Gene 
Expression’s CT Difference formula (Figure 4). The formula compares a gene of interest 
relative to a housekeeping gene in a particular treatment sample to a reference sample 
usually designated as the experimental control. This analysis technique accounts for 
variant PCR efficiencies and permits relative quantification of a gene of interest without 
knowledge of an initial gene copy number or standard curve (Schefe et al. 2006). For 
this study, our reference sample was our positive control of TGF-ß cellular stimulation. In 
addition, our housekeeping gene, which should be unaffected by varying cellular 









(1+ E($actin))"#CT ($actin )  
Figure 4. Gene Expression’s CT Difference Formula: Relative Expression Ratios 
(rER). This formula was used to determine the relative expression of FN among 
experimental treatment groups assessing Ac-SDKP bioactivity. Rnorm, normalized 
fluorescence; SOI, sample of interest; ref, reference sample; E(FN), efficiency of FN; 
E(ß-actin), efficiency of ß-actin;  







All cellular treatments included simultaneous stimulation of FN expression by 
TGF-ß. Results reveal, consistent with current literature, cells exposed to free Ac-SDKP 
substantially down regulate FN mRNA expression. Resultant mRNA expression is 70% 
below levels obtained from cells solely stimulated by TGF-ß (Guo et al. 2004, Hocevar et 
al.1999). For empty PK3 particle treatments, particles were administered at 
concentrations as if loaded with 1% (w/w) Ac-SDKP that correlated with free Ac-SDKP 
dosing. We further increased empty particle concentrations 10 fold from those 
correlating to free SDKP administration to ensure evident responses. The empty PK3 
particle cellular treatment demonstrates an insignificant affect on FN expression. In 
addition, cells were exposed to 1.2% Ac-SDKP loaded particles synthesized by the s/o/w 
emulsion technique at the same concentration as empty particles. Results illustrate a FN 
relative expression ratio (rER) as compared to the positive control (TGF-ß only 
stimulation) of 1.65. Concurrently, pre extracted Ac-SDKP from the same particle batch 
and similar dosing to free SDKP also induced an up regulation of Fn expression with a 
relative expression ratio of 1.45. Upregulation of FN expression due to exposure to 
previously processed Ac-SDKP indicates severe loss of bioactivity. Peptide processing 
appears to have an adverse effect on FN expression leading to overproduction above 









Figure 5. Relative Fibronectin mRNA Expression Ratio Following Ac-SDKP 
Treatment. Cells were simultaneously exposed to TGF-ß with indicated treatments for 8 
hours and relative Fn expression ratios were determined by qPCR. Treatments included 
TGF-ß alone, empty PK3 particles, free Ac-SDKP, Ac-SDKP loaded particles, and pre-
extracted Ac-SDKP from loaded particles. rER’s were determined using the Gene 

















Use of polyketal microparticles as a drug delivery vehicle can expand non-
invasive treatment possibilities specified for pulmonary applications.  In this study, we 
proposed we could optimally load the model therapeutic, Ac-SDKP, into polyketal 
microparticles possessing aerodynamic properties conducive for aerosolization. We 
identified key parameters such as the emulsion device, pH, drug/polymer formulation, 
and type of emulsion in the particle synthesis process that have influence on peptide 
loading and particle size distribution. Systematic alterations of these parameters and 
characterization of resultant particles allowed us to maximize Ac-SDKP loading while 
adhering to aerodynamic size constraints. 
 Through evaluation of Ac-SDKP loading we found a probe sonicator is the only 
apparatus capable of effectively emulsifying the primary emulsion of the particle 
synthesis process. Use of a homogenizer or vortex does not supply the agitation 
necessary to properly disperse the peptide throughout the inner organic phase of the 
double emulsion. This failure is likely due to peptide emulsion droplets being too large 
and thus thwarting the possibility of the polyketal to form a microsphere surrounding the 
peptide.  The pH of the outer aqueous phase of the double emulsion did have a slight 
positive affect on Ac-SDKP loading, but had more influential effect on particle size.  At 
acidic pHs, particle size ranged from approximately 20-40 um, which is incompatible with 
aerosolization. This trend is consistent with previous studies (Peltonen 2004). The initial 
peptide/polymer formulation appeared to have minor affects on final Ac-SDKP loading.  
We discovered that an initial 15% drug to polymer ratio slightly increases final loading. 
With more peptide available for encapsulation during the processing, the probability of 
entrapment is likely increased. However, the aforementioned particle synthesis 
parameters do not have a robust effect on final Ac-SDKP loading. Therefore, we further 





 We performed a synthesis technique specified for the creation of porous particles 
since previous trials resulted in non-porous particles too large for aerosolization. During 
particle processing, the polyketal polymer was dissolved in a mixture of two organic 
solvents with distinct boiling points. At the solvent evaporation step, the less volatile 
solvent remained trapped within hardened, formed microparticles. Then upon 
evaporation of the entrapped solvent, pores were formed as the solvent released from 
the particles. This procedure was successful in creating aerodynamically suitable 
particles, but lacked sufficient Ac-SDKP loading.  In addition, a cryo w/o/w emulsion 
method was assessed. This method involved snap freezing the primary emulsion, so Ac-
SDKP loss to the outer aqueous phase of the secondary emulsion was minimized. 
Again, this method displayed slight increases in Ac-SDKP loading but failed to maintain 
prescribed aerodynamic constraints. This was likely due to the inability of the 
homogenizer to completely unify the mixture due it being partially frozen leading to larger 
particles. 
 Lastly, a solid in water in oil emulsion was performed in attempt to attain particle 
design specifications. The procedure was comparable to the basic w/o/w technique 
previously used, except we emulsified solid peptide within the inner organic phase of the 
primary emulsion. This technique significantly increased peptide loading and produced 
particles within a range suitable for aerosolization. Peptide loss to the outer aqueous 
phase of the secondary emulsion was likely minimized due to the lengthen duration the 
peptide remained in the organic phase.  The peptide must first dissolve in the aqueous 
phase for loss to occur, which increases the probability polyketal polymer will 
encapsulate the peptide. Resultant Ac-SDKP loading ranged from 0.5%-1.9% (w/w) 
which should translate to clinical dosing requirements.  Previous studies have shown a 1 
mg/kg dose of Ac-SDKP was effective in asserting anti-fibrotic effects. Therefore 0.5% 





 Once particles were produced at Ac-SDKP loading levels translatable to clinical 
dosing needs, the bioactivity of the released peptide was examined. From past studies, it 
is known that TGF-ß induced FN expression is effectively down regulated by the peptide 
Ac-SDKP (Guo et al. 2004, Hocevar et al.1999). By quantifying FN mRNA levels after in 
vitro stimulation of cells with TGF-ß followed by treatment with Ac-SDKP loaded 
microparticles, peptide bioactivity was assessed.  Results indicated that Ac-SDKP 
extracted from previously synthesized particles as well as loaded particles unexpectedly 
upregulated FN mRNA expression in primary fibroblasts.  In contrast, free Ac-SDKP 
inhibited FN expression and empty PK3 particles had no significant effect on FN 
expression. This suggests there are alterations to the peptide due to the particle 
synthesis process.  Throughout the particle synthesis process the peptide is subjected to 
various treatments including exposure to organic solvents and intense mechanical 
manipulations that could have adverse effects on its bioactivity. Future studies will have 
to determine the stage in the particle synthesis process peptide alterations occur and 
how structurally the peptide is distorted. If this can be determined then it may be 




















It is vital for pulmonary applications that delivered substances do not elicit a 
significant inflammatory response.  As observed in many chronic lung disorders, 
inflammation is a salient feature and facilitates fibrotic events leading to lung function 
compromise.  Therefore, an effective delivery vehicle should not exacerbate the already 
inflamed tissues and exhibit exceptional biocompatibility. To assess polyketal 
biocompatibility, responses to particle exposure were investigated both in vivo and in 
vitro.  The in vivo assessment involved the intratracheal injection of empty particle 
suspensions (both PLGA and PK3) into murine models and subsequent analysis of 
bronchoalveolar lavage (BAL) fluid as well as histological examination. The BAL and the 
histological examination should reveal any increase in inflammatory and/or immune cells 
due to particle presence. Also, injection of PLGA particles will permit the demonstration 
of PK3 as a superior biocompatible biomaterial.  The in vitro study, performed with the 
U937 monocytic cell line, aims to reveal any cell activation causing IL-1 expression due 
to exposure to the particles. Ideally, inflammatory responses as well as cytokine 





PK3 polymer (donated by the Murthy lab), Poly (dl- lactide/glycolide) 50:50 
(Polysciences, Inc., Warrington, PA) U937 IL-1 (Interleukin-1) luciferase reporter 





VA), Fetal Bovine Serum (Mediatech, Herndon, VA), Penicillin-Streptomycin (Mediatech, 
Herndon, VA), CellGro COMPLETE media (Mediatech, Herndon, VA), 
Lipopolysaccharide (Sigma, St. Louis, MO), Luciferase Detection kit (Promega, Madison, 
WI) C57 BL6 male mice (Jackson Labs, Campbell, CA) ketamine/xylazine, 10% buffered 
Formalin (VWR International, Suwanee, GA), Lueco Stat Kit (Fisher Scientific, 
Pittsburgh, PA), Hematoxylin and Eosin stain (Richard-Allan Scientific, Kalamazoo, MI), 
Paraffin (Surgipath Medical Industries, Richmond, IL). 
 
4.2.2 Empty Particle Synthesis 
Synthesis of empty particles was achieved by a double emulsion technique 
similar to previously described methods. Particle size and morphology were 
characterized by DLS and SEM respectively. 
 
4.2.2.1 PK3 Particle Synthesis 
  PVA (1%, 500 ul) at pH 8.5 was added to an 8ml glass vial. In a separate 24 ml 
glass vial, 500 mg of PK3 was dissolved in 5 ml of dichloromethane (DCM) to also yield 
a 100 mg/ml solution. The PK3 in DCM solution was then added to the 1% PVA solution 
and emulsified with the homogenizer (level 5) for 1.5 min. Immediately, 20 ml of a 5% 
PVA buffered (pH 6.8) solution was added to this primary emulsion and homogenized 
(level 3) for 1.5 min yielding the secondary emulsion. The emulsion was added to a 500 
ml round bottom flask and DCM is removed with the use of a Rotovap. The flask was 
rotated at speed 3 for the duration of the evaporation process, which included cycling the 
mixture between low and high pressures over the course of approximately 10-15 min. 
Contents of the 500 ml round bottom flask (particle suspension) were then dispensed 
into a 50 ml conical tube and diluted with deionized water to approximately 50 ml.  A 1 





to determine particle size distributions.  The particle suspension was then centrifuged for 
10 min at 7000xg. The supernatant was removed and particles resuspended by 
vortexing with 40 ml of fresh deionized (DI) to remove PVA. Centrifugation was 
repeated. The supernatant was again removed and the particles resuspended with fresh 
DI water. The suspension was frozen for approximately 45 min at -80 C. Frozen particle 
suspension was lyophilized overnight. This procedure was repeated to yield an 
approximate 1 g batch of empty particles. 
 
4.2.2.2 PLGA Particle Synthesis 
PVA (1%, 500 ul) at pH 8.5 was added to an 8ml glass vial. In a separate 24ml 
glass vial, 500 mg of PLGA was dissolved in 5ml of dichloromethane (DCM) to also yield 
a 100 mg/ml solution. The PLGA in DCM solution was added to the 1% PVA solution 
and emulsified with the homogenizer (level 5) for 1.5 min. Immediately, 20 ml of a 5% 
PVA buffered (pH 6.8) solution was added to this primary emulsion and homogenized 
(level 4) for 1.5 min yielding the secondary emulsion. The emulsion was added to a 500 
ml round bottom flask and DCM is removed with the use of a Rotovap. The flask was 
rotated at speed 3 for the duration of the evaporation process, which included cycling the 
mixture between low and high pressures over the course of approximately 10-15 min. 
Contents of the 500 ml round bottom flask (particle suspension) were then dispensed 
into a 50 ml conical tube and diluted with deionized water to approximately 50 ml.  A 1ml 
aliquot of the particle suspension was reserved for dynamic light scattering analysis to 
determine particle size distributions.  The particle suspension was then centrifuged for 
10 min at 7000xg. The supernatant was removed and particles resuspended by 
vortexing with 40 ml of fresh deionized (DI) water in order to wash and remove PVA. 
Centrifugation was repeated. The supernatant was again removed and the particles 





80 C. Frozen particle suspension was lyophilized overnight. This procedure was 
repeated to yield an approximate 1 g batch of empty particles. 
 
4.2.3 In Vitro Cytokine Response to Particles 
U937 cells (monocytic) transfected with an IL-1 luciferase reporter construct, 
were transitioned into CellGro COMPLETE serum free media from growth media (RPMI 
1640) over two days. We seeded cells at a density of 500,000 cells/well (200 ul) in a 48 
well plate and then allowed the cells to reach a state of quiescence in serum free media 
over 36 hrs. PLGA and PK3 particles were suspended at a concentration of 0.7 mg/ml in 
serum free media and LPS dissolved in media at a concentration of 3 ug/ml. Both 
particle suspensions (100 ul) as well as LPS (100 ul) were added to the cells in triplicate 
for two time points (24, 48 hrs). For a negative control, 100 ul of culture media was 
added in triplicate for 3 time points: 0, 24, 48 hrs. At specified time points, well contents 
were aspirated and placed in a 1.5 ml Eppendorf tube. The tubes were then centrifuged 
at 10,000 rpm for 10 min to pellet cells and particles. The supernatant was carefully 
removed and pellet stored in a clean eppendorf tube at -20 C for later analysis of 
luciferase activity. 
We quantified luciferase activity using a luciferase activity assay by Promega. 
Cell pellets were lysed in luciferase assay lysis buffer (50 ul) and sonicated for 10 sec. 
Then 20 ul of each lysed sample was added to an opaque microplate. We added 50 ul of 
the luciferase substrate and read luminescence after 3 min.  A total protein assay was 
also performed to account for minor variations among sample cell numbers.  We added 
10 ul of the lysed sample to a clear microplate and added 200 ul of 1:4 diluted Bio Rad 
dye reagent.  Absorbance was read at 595 nm.  Luminescence values were all 






4.2.4 Intratracheal Particle Injections (Murine Model) 
Particles were injected intratracheally into C57 BL6 male mice (20-25g) to assess 
polyketal biocompatibility in vivo. All mice were anesthetized according to IUCUC 
standards by injection interperitoneally with 200 ul of ketamine/xylazine solution (approx. 
80mg/kg ketamine + 10 mg/kg xylazine). Then a small incision was made at the throat to 
expose the trachea. Using a sterile syringe, the trachea was punctured and particle 
suspensions injected. Experimental groups included particle suspensions composed of 
1.5 mg of PK3 (n=3) and 1.5 mg of PLGA (n=3) in 50 ul of sterilized PBS. In addition, 
control groups included bleomycin as a positive (n=2), PBS as a vehicle (n=2), and 
unadulterated mice as a negative (n=2). After injections, mice were sutured and left to 
recover. For the experimental and bleomycin groups, mice were sacrificed at days 1, 4, 
and 7. For the vehicle control, mice were sacrificed at day 5, and the unadulterated 
control group at day zero. Immediately following sacrifice by sufficient CO2 (approx. 3 
min) gas inhalation a bronchoalveolar lavage was performed and the lung harvested. 
 
4.2.5 Bronchoalveolar Lavage (BAL) 
Once the mice were euthanized by CO2 gas, the throat was again cut to expose 
the trachea. A syringe with 1.5 ml of sterile PBS was dispensed into the trachea and 
subsequently filled all five lobes of the lung. After the syringe was completely plunged, 
the dispensed PBS was then recovered by suction of the syringe. Cells and fluid 
collected were place on ice in 1.5 ml Eppendorf tubes. Following centrifugation at 4000 
rpm for 7 min, cell pellets were resuspended in 100 ul of PBS. BAL samples were 
prepared for staining and quantification by standard cytospin procedures. Using the 
Cytospin 2 (Shandon Inc.) cells were centrifuged onto slides at 1500 rpm for 7min. 






4.2.6 Lung Harvesting and Histology Examination Preparation 
Immediately following the BAL, lungs were harvested from at least one mouse 
from each time point and experimental/control group. Skin and various internal organs 
were resected systematically to harvest the lungs.  The trachea was cannulated and left 
in tact upon removal of the lungs from the body. Using the cannula, the lungs were 
inflated with 10% buffered formalin and then stored in 15 ml of 10% buffered formalin 
until paraffin embedding. Lungs were embedded in paraffin and sectioned into 5 um 
slices. Slices were processed according to standard techniques and stained with 
hematoxylin and Eosin (H&E) on slides. 
 
4.3 Results 
4.3.1 Empty Particle Characterization 
Empty PK3 and PLGA particles were evaluated by size and morphology. We 
aimed to produce particles that were consistent with loaded particles previously 
synthesized as well as with the prescribed size design criteria. PLGA and PK3 particles 
were synthesized in two batches. Both batches of each polymer were combined before 
intratracheal administration. Particles size and morphology are detailed in Table 7 and 
Figure 6 respectively. 
 
Table 7. Summary of Particle Characterization For The Animal Study. Diameters 
and polydispersity measurements were obtained from the DLS instrument. Batches were 
combined prior to intratracheal injection into the murine model. 
 
Particle Batch Effective diameter (um) Polydispersity 
PK3 Batch 1 1.06  0.074 
PK3 Batch 2 0.89 0.005 
PLGA Batch 1 0.77 0.005 


















Figure 6. SEM of Particles Used For Intratracheal Injections. Empty PLGA and PK3 
particles were synthesized for use in intratracheal injections into a murine model.  
Particles were created in two separate batches that were combined prior to injections. 
Images are representative of the particles injected and are from one of the two batches 






4.3.2 Bronchoalveolar Lavage Analysis 
To determine pulmonary biocompatibility of polyketals, we intratracheally injected 
1.5 mg of particles into a murine model. For comparison, the current commonly used 
biomaterial for drug delivery, PLGA, was also injected to demonstrate PK3’s superiority 
in minimizing inflammation induction. The controls included injection of a known 
inflammation inducer, bleomycin, the vehicle, PBS (sacrificed at day 5), and an 
unadulterated control. Particle treatment as well as bleomycin groups were sacrificed at 
the 1, 4, and 7 day time points for BAL analysis and histological examination. After 
procuring BAL fluid and affixing collected cells to slides, we performed a cell count of 
major inflammatory/ immune cells. Results indicate the starkest contrast with 
macrophage counts among treatment groups (Figure 7). At day 1, the PK3 treatment 
group exhibits no statistical difference from unadulterated and vehicle controls; whereas, 
PLGA shows extreme significance from negative controls, suggesting a heighten 
inflammatory response. At day 4, both PK3 and PLGA particle groups demonstrate 
increased infiltration of macrophages. However, by day 7 for PK3 injections, 
macrophage levels abated, while PLGA induced macrophage counts continued to 
increase. Assessment of lymphocytosis revealed at day 4, PLGA may elicit a slight cell 
mediated immune response. In contrast, PK3 facilitated lymphocyte counts among all 
time points, remained similar to basal levels. Lastly, examination of BAL fluid neutrophil 
content displayed a slight increase at day 1 in PK3 induced neutrophil infiltration as 
compared to the unadulterated control group. However, for days 4 and 7, populations of 
neutrophils for both PK3 and PLGA groups, were not statistical variant from negative 



























Figure 7. Bronchoalveolar Lavage Analysis After Intratracheal Particle Injections. 
PK (n=3) and PLGA (n=3) particles were injected and BAL fluid analyzed for 
inflammatory/immune cell content. Control groups included bleomycin (Bleo, positive, 
n=2), vehicle (PBS, negative, n=2), and unadulterated mice (Con, negative, n=2). 











4.3.3 Histological Assessment of Polyketal Effect 
Following BAL fluid procurement, at least one lung from each time point and 
experimental group was extracted for histological examination. We assessed, 
qualitatively, stained lung slices based on inflammatory cell presence and lung structure. 
Slides were scored based on the following scale: 0, no inflammation; 1, some 
inflammation; 2, more inflammation; and 3, most inflammation. Results appear to 
corroborate BAL data in that PK3 particles do not induce significant inflammatory 
responses (Figure 8, 9). Scoring suggests PLGA is more inflammatory than PK3 with 
elevated scores at days 1 and 4. However, in contrast to cellularity data, on day 7, 
resultant PK3 scoring indicated increase inflammation above PLGA levels. Despite 
trends observed, histologically, there is very little variance and no statistical significance 
among experimental groups. In addition, as a result of the lungs being unperfused, large 
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Figure 8. Histological Assessment of Particle Effect. Lungs were stained with H&E 
after intratracheal injections of 1.5 mg of PK or PLGA particles, bleomycin (BLEO), PBS, 









Figure 9. Histological Scoring After Intratracheal Particle Injections. Lungs were 
stained with H&E and scored after intratracheal injections of 1.5 mg of PK or PLGA 
particles, bleomycin (BLEO), PBS, or no treatment (CON). PBS vehicle controls were 
sacrificed on day five. Score scale (n=3): 0, no inflammation; 1, some inflammation; 2, 













4.3.4 Cytokine Production in Response to Particles 
U937 cells, stably transfected with an IL-1 luciferase reporter construct, were 
used to examine cytokine production in response to both PLGA and PK3 particles.  We 
exposed cells to particles concentrations (approx. 0.07mg/well) identical to those used in 
our previous experiment investigating TGF-ß induced FN expression. Luciferase activity 
was normalized to total protein levels in each sample to account for minor well to well 
variations in cell numbers.  Results indicated no significant increase in IL-1 expression 
due to either polymer formulation.  By 48 hours, however, total IL-1 expression appears 
to diminish uniformly across samples. This reduction of expression coincides with 
observed contamination within the cell populations.  We attempted to minimize risk of 
bacterial contamination; however, due to the non-sterile particle production conditions 
this was unavoidable.  The particles and LPS were resuspended in initially sterile 
CellGro COMPLETE media, but the resuspension procedure was not performed 
aseptically. The inherent lack of sterility associated with the particles and procedure 
likely contributed to cell contamination and death leading to decreased detection of IL-1 



















Figure 10. Particle Induced IL-1 Expression.  U937 IL-1 luciferase reporter constructs 
were exposed to PLGA and PK3 particles at identical concentrations over 48 hrs. The 
controls included LPS as the positive and unstimulated cells as the negative. Luciferase 















Pulmonary disorders marked by fibrotic scarring are intensified by inflammation.  
Therefore, it is essential to for any substance delivered to alveolar regions to minimize 
inflammation induction. To assess PKMs’ viability as a small molecule drug delivery 
vehicle, empty PK3 particles as well as PLGA particles were synthesized according to 
aerodynamic design criteria. After injection of both polymeric particles into murine 
models, BAL fluid was analyzed for increases in inflammatory/immune cells. In addition 
a histological assessment was performed to determine any adverse particle influence. 
 We included PLGA in this study because it is one of the biomaterial standards of 
delivered microparticles. It is commonly used as a therapeutic carrier, but its applicability 
in pulmonary drug delivery is limited.  In previous studies and in this current study PLGA 
induces significant inflammatory responses and possibly slight cell mediated immune 
activation. Macrophage populations illustrate significant (p<0.001) elevation from control 
groups at days 1, 4, and 7 due to PLGA particles. Macrophage influx by day 7 continues 
to trend upward, 3x above basal levels.  Concurrently, at day 4 PLGA particles elicit 
minor lymphocyte influx, possibly indicating a cell mediated immune response to the 
particles. However, neutrophil populations were consistently elevated from basal levels, 
but not significantly.  
In contrast to PLGA, PK3 injected particles inflamed lung tissue to a lesser 
degree. At day one, macrophage numbers remained similar to control values, by day 4 
macrophage influx increase but to a lesser extent than PLGA groups (p<0.01). 
Macrophage infiltration subsided by day 7 closer to basal values (p<0.05); whereas, 
PLGA particles continued to induce macrophage influx on day 7. Lymphocyte values 
throughout the study remained comparable to control group levels, suggesting no cell 
mediated immune responses from PK3 particles. However, on day 1, neutrophil 





levels by day 4 and 7. This indicates minor inflammation, but also demonstrated effective 
and rapid resolution.  
In addition the histological examination of lung structures revealed minimal 
inflammation. Lung visualization and scoring appeared similar among experimental 
groups indicating no major histological changes due to the particles.  This is consistent 
with previous studies. Typically, bleomycin induced histological lung alterations do not 
be come evident until day 8-10. 
In vitro investigation of particle induction of IL-1 expression, an inflammatory 
cytokine, revealed insignificant IL-1 production. PLGA does appear to elicit more IL-1 
expression than PK3, however differences are statistically insignificant. These results 
suggest that the particles, both PLGA and PK3, do not cause overproduction of 
inflammation facilitating cytokines. However, results may be skewed to due to the 
bacterial contamination observed by 48 hrs.  It may be beneficial to develop a sterile 
particle synthesis technique or to produce particles in a sterile environment before 
repeating in vitro investigations on particles. 
Overall, the most salient difference in cell populations for the two polymers was 
observed with macrophages.  PLGA more efficiently activated inflammatory responses, 
which would be detrimental for pulmonary fibrotic disorders. Therefore, PK3 is a superior 
biomaterial for pulmonary applications. Although, PK3 elicits inflammatory responses 
distinctively elevated from basal levels, data indicates rapid resolution of the heightened 
inflammatory response.  This distinguishes PK3 as an ideal candidate for a pulmonary 














Certain lung diseases characterized by excessive ECM deposition such as 
pulmonary fibrosis, have remained resistant to current treatments. These diseases are 
progressive in nature and likely require non-invasive therapy in order to halt or possibly 
reverse pathological alterations to the lung.  Using polyketal microparticles as a drug 
delivery vehicle has the potential to expand non-invasive treatment possibilities. Through 
inhalation, novel therapeutic biomolecules can be encapsulated within polyketals and 
delivered non-invasively to alveolar regions of the lung.  
The present study demonstrated that PK3 polyketal microspheres are an ideal 
therapeutic delivery vehicle for pulmonary applications due to its tissue biocompatibility.  
With inflammation facilitating fibrotic events prominent in many chronic lung diseases, 
tissue biocompatibility is an especially pertinent property.  PK3 particles intratracheally 
injected into a murine model displayed limited inflammation induction based on BAL fluid 
cellularities.  By day seven, following particle injections, macrophage, lymphocyte, and 
neutrophil levels were comparable to both the vehicle and unadulterated controls. 
However, the more commonly used biomaterial, PLGA, failed to clear inflammatory cells 
by day seven illustrating PK3’s superior biocompatibility.  
 Furthermore, we have developed a particle synthesis procedure suitable for 
sufficient encapsulation of a small hydrophilic peptide. Through a solid in oil in water 
double emulsion technique, our model therapeutic attained load efficiencies translatable 
to clinical dosing requirements despite possessing little affinity for the hydrophobic 
polymer.  In addition, this synthesis technique produced particles within the size 





inhalation. However a major limitation of the particle synthesis procedure is it appears to 
render Ac-SDKP biologically inactive.  The processing of loaded microparticles includes 
harsh chemical and mechanical manipulations that could affect the bioactivity of this 
particular peptide.  Further studies will have to be performed to identify how the peptide 
is altered and where in the processing procedure alterations occur.  With this data, 
restoration of processed Ac-SDKP bioactivity may be attainable. 
 
5.2 Investigation of Ac-SDKP Bioactivity Loss After Processing 
Our study revealed a significant loss of Ac-SDKP bioactivity ensuing 
encapsulation within PK3 microparticles.  For Ac-SDKP to be an effective locally 
delivered anti-fibrotic to alveolar regions, it is imperative to elucidate the source of the 
peptide’s inactivation.  To identify the cause of Ac-SDKP dysfunction, we will isolate 
each step of the particle synthesis procedure and characterize its affect on Ac-SDKP. 
We will evaluate preservation of Ac-SDKP’s chemical structure using mass 
spectroscopy. In addition, peptide bioactivity will be assessed through its efficacy in FN 
expression inhibition at each stage of the particle preparation protocol.  Once we 
distinguish which particular particle synthesis manipulations inactivate the peptide, it 
may be possible to alter synthesis techniques or the peptide to restore activity. 
 
5.3 Ac-SDKP Loaded Particle Reversal of Bleomycin Induced Fibrosis 
Presuming a technique permitting Ac-SDKP encapsulation within PK3 
microparticles preserving bioactivity is developed, we will investigate loaded 
microparticle efficacy in the prevention/ reversal of bleomycin induced pulmonary 
fibrosis. Using a murine model we will intratracheally administer empty polyketal 
microspheres, free Ac-SDKP, and Ac-SDKP loaded particles at day 0, 7, and 14 





and negative controls and lungs assessed for fibrotic content.  By performing a 
hydroxyproline assay on harvested lung tissue, ECM collagen content can be quantified 
and related to the extent of fibrotic progression.  From this data, we can evaluate Ac-
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